A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the ... (NCT06335173)

Migration, Crosslink

📖

A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the ... (NCT06335173)

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct06335173

📖 Wiki Page

clinical2628 wordssynced 2026-04-02

ALTITUDE-AD: Sabirnetug (ALZ-201) Phase 2 Trial in Early Alzheimer's Disease

Overview

ALTITUDE-AD (NCT06335173) is a Phase 2 double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of intravenous Sabirnetug (also known as ALZ-201) in patients with early Alzheimer's disease. Sponsored by Acumen Pharmaceuticals, this trial represents a critical step in developing novel disease-modifying therapies targeting amyloid-beta pathophysiology.

Sabirnetug is a monoclonal antibody designed to selectively target and neutralize toxic amyloid-beta oligomers, which are widely recognized as the primary drivers of synaptic dysfunction and neurodegeneration in AD[@aby2020]. Unlike earlier antibody approaches that focused primarily on monomeric Aβ or plaque removal, Sabirnetug specifically targets the soluble, synaptotoxic oligomeric species believed to be most pathogenic.

This Phase 2 trial builds upon earlier preclinical work demonstrating that ALZ-201 effectively reduces Aβ oligomer-induced synaptic damage in cellular and animal models. The selection of the integrated Alzheimer's Disease Rating Scale (iADRS) as the primary endpoint reflects the growing recognition that composite cognitive-functional measures capture clinically meaningful treatment effects more sensitively than individual cognitive scales alone.

Trial Details

...

ALTITUDE-AD: Sabirnetug (ALZ-201) Phase 2 Trial in Early Alzheimer's Disease

Overview

ALTITUDE-AD (NCT06335173) is a Phase 2 double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of intravenous Sabirnetug (also known as ALZ-201) in patients with early Alzheimer's disease. Sponsored by Acumen Pharmaceuticals, this trial represents a critical step in developing novel disease-modifying therapies targeting amyloid-beta pathophysiology.

Sabirnetug is a monoclonal antibody designed to selectively target and neutralize toxic amyloid-beta oligomers, which are widely recognized as the primary drivers of synaptic dysfunction and neurodegeneration in AD[@aby2020]. Unlike earlier antibody approaches that focused primarily on monomeric Aβ or plaque removal, Sabirnetug specifically targets the soluble, synaptotoxic oligomeric species believed to be most pathogenic.

This Phase 2 trial builds upon earlier preclinical work demonstrating that ALZ-201 effectively reduces Aβ oligomer-induced synaptic damage in cellular and animal models. The selection of the integrated Alzheimer's Disease Rating Scale (iADRS) as the primary endpoint reflects the growing recognition that composite cognitive-functional measures capture clinically meaningful treatment effects more sensitively than individual cognitive scales alone.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06335173 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Acumen Pharmaceuticals |
| Enrollment | 542 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2024-02-29 00:00:00 |
| Completion Date | 2026-10-01 00:00:00 |
| Last Updated | 2025-10-27 00:00:00 |

Conditions Studied

Alzheimer Disease (Early Stage, including MCI due to AD and mild AD dementia)

Mechanism of Action

Targeting Toxic Amyloid-Beta Oligomers

Sabirnetug (ALZ-201) represents a next-generation therapeutic approach that specifically targets the soluble amyloid-beta oligomeric species that are now recognized as the most synaptotoxic form of Aβ in AD pathogenesis.

Pathological Rationale:

Amyloid-beta monomers are naturally occurring peptides that, in healthy brains, are cleared efficiently
Aβ oligomers form when Aβ peptides aggregate into soluble, diffusible species containing 2-50 monomers
Plaques (insoluble Aβ deposits) may actually serve as a "sink" for toxic oligomers, and their removal without targeting oligomers directly may provide limited clinical benefit

The oligomer hypothesis proposes that soluble Aβ oligomers, rather than plaques themselves, are the primary drivers of:

Synaptic dysfunction and loss
Dendritic spine degeneration
Impaired long-term potentiation (LTP)
Neuroinflammation through microglial activation
Progressive cognitive decline[@aby2020]

Antibody Design and Specificity

Sabirnetug is designed to:

Selectively bind Aβ oligomers with high affinity, while showing minimal binding to monomers and plaques

Neutralize synaptotoxic activity by blocking oligomer interactions with neuronal receptors

Promote clearance of oligomeric species through Fc-mediated microglial phagocytosis

Avoid excessive plaque disruption that might trigger inflammatory responses

This selective targeting approach differs from earlier-generation anti-Aβ antibodies like aducanumab and lecanemab, which primarily target plaque amyloid with varying degrees of efficacy.

Amyloid Cascade in AD Pathogenesis

The amyloid cascade hypothesis, first proposed in 1992 and subsequently refined, posits that Aβ accumulation is the initiating event in AD pathogenesis:

Mermaid diagram (expand to render)

However, the failure of multiple Abeta-targeting therapies has led to significant reappraisal of this model, with current understanding emphasizing:

Abeta as necessary but not sufficient for disease
Multiple upstream triggers (genetic, environmental, aging-related)
Complex interactions between Abeta, tau, and neuroinflammation["@amyloid2023"]

Study Design Details

Trial Structure

This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial with the following key features:

| Design Element | Description |
|---------------|-------------|
| Randomization | 1:1:1 to two active dose cohorts or placebo |
| Duration | 78 weeks (approximately 18 months) |
| Blinding | Double-blind (participant and investigator) |
| Setting | Multi-center, international |
| Phase | Phase 2 |

Treatment Arms

The trial evaluates multiple dose levels to establish:

Dose-response relationship for efficacy
Safety and tolerability across dose range
Pharmacodynamic markers of target engagement
Optimal dosing regimen for Phase 3

Primary Endpoint

Integrated Alzheimer's Disease Rating Scale (iADRS):

Composite measure combining:
ADAS-Cog14 (cognitive subscale, 14 items) - assesses memory, language, praxis
ADCS-iADL (functional subscale) - assesses daily living activities
Range: 0-146 (lower = worse function)
Designed to capture both cognitive and functional domains in a single sensitive measure
Previously validated in trials of early AD populations

Secondary Endpoints

Secondary endpoints likely include:

Amyloid PET (Centiloid reduction) - measure of Aβ plaque burden
CSF biomarkers - Aβ42/40 ratio, tau, p-tau levels
Clinical measures - MMSE, CDR-SB
Safety - adverse events, SAEs, immunogenicity

Eligibility Criteria

Inclusion Criteria (Anticipated)

Disease-related:

Age 50-85 years
Clinical diagnosis of MCI due to AD or mild AD dementia
MMSE score 20-30 (or equivalent)
Confirmed amyloid positivity (PET or CSF)

Other:

Stable background medications for >4 weeks
Adequate caregiver/support person availability
Ability to comply with protocol requirements

Key Exclusion Criteria

Neurological: Stroke, significant vascular disease, other dementia types
Psychiatric: Severe depression, psychosis, active suicidal ideation
Medical: Uncontrolled hypertension, diabetes, cardiac disease
Medications: Current anti-Aβ therapy, immunomodulatory agents

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Neuroinflammation in AD

A key component of AD pathophysiology that Sabirnetug may address through indirect effects on oligomer-mediated microglial activation:

The innate immune system plays a critical role in AD pathogenesis, with microglia and astrocytes contributing to both protective and pathogenic processes:

Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) are elevated in AD brain and correlate with disease severity
Microglial morphometry shows disease-associated changes in density and distribution around plaques
Complement system activation contributes to synaptic elimination
Aβ oligomers directly activate microglia through pattern recognition receptors[@tnp2022]

Understanding Sabirnetug's effects on neuroinflammation will be important for evaluating its overall disease-modifying potential.

Clinical Significance

Advancing the Anti-Aβ Pipeline

This trial represents one of several ongoing efforts to develop effective Aβ-targeted therapies:

| Agent | Company | Target | Stage | Key Differentiator |
|-------|---------|--------|-------|-------------------|
| Lecanemab | Eisai/Biogen | Aβ protofibrils | Approved | Early approval, confirmatory trial |
| Donanemab | Eli Lilly | N-terminal Aβ | Approved | Tartrate, staged dosing |
| Remternetug | Eli Lilly | Aβ oligomers | Phase 3 | Subcutaneous administration |
| Sabirnetug | Acumen | Aβ oligomers | Phase 2 | Selective oligomer targeting |

Challenges in AD Drug Development

The field has learned important lessons from previous Aβ antibody trials:

Patient selection - Treating earlier disease stages appears more effective

Endpoint sensitivity - Composite measures like iADRS may be more sensitive

Biomarker correlation - Amyloid reduction necessary but not sufficient

Safety monitoring - ARIA requires careful imaging surveillance

Combination approaches - Rationale for multi-target therapy

Implications for AD Treatment

If successful, Sabirnetug would:

Validate oligomer targeting as an effective therapeutic strategy

Provide treatment option with novel mechanism of action

Inform precision medicine approaches based on biomarker profiles

Enable combination therapy development with other mechanisms

Participating Sites

The trial is being conducted at multiple centers worldwide, including sites in:

California, United States (multiple locations including Carlsbad, Fullerton, Irvine, Long Beach, Santa Ana)
Additional international locations (specific sites to be confirmed)

[Clinical Trials Overview](/clinical-trials/overview)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyloid Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)

Safety and Tolerability Considerations

All anti-Aβ antibodies carry the risk of amyloid-related imaging abnormalities (ARIA), a class of imaging findings that include:

ARIA-E (Edema):

Characterized by hyperintense signal on FLAIR MRI
Represents vasogenic edema or sulcal effusions
Typically reversible upon drug discontinuation
Risk factors include ApoE ε4 carrier status, higher dosing

ARIA-H (Hemorrhage):

Includes cerebral microhemorrhages, hemosiderosis
May occur with or without ARIA-E
Generally asymptomatic but requires monitoring

Monitoring Protocol:

Baseline MRI before first dose
MRI at Week 12, Week 24, and as clinically indicated
Careful monitoring for symptoms (headache, confusion, visual changes)
Dose adjustment guidelines based on ARIA severity

Immunogenicity

As a monoclonal antibody, Sabirnetug may elicit anti-drug antibodies (ADAs):

ADAs could affect PK/PD and reduce efficacy
Potential for infusion reactions
Long-term immunogenicity monitoring in extension studies

Comparison with Approved Aβ Antibodies

| Parameter | Lecanemab | Donanemab | Sabirnetug |
|-----------|-----------|-----------|------------|
| Target | Protofibrils | N-terminal | Oligomers |
| Dosing | Q2W IV | Q4W IV | TBD |
| ARIA-E rate | ~10% | ~24% | TBD |
| ARIA-H rate | ~17% | ~31% | TBD |
| Infusion time | 60 min | 60 min | TBD |

Competitive Landscape and Market Context

AD Treatment Market

The Alzheimer's disease treatment market represents one of the largest unmet medical needs:

Global AD population: ~55 million (2023)
Projected to reach 139 million by 2050
Market for disease-modifying therapies: >$10B annually

Key Players and Pipeline

Eisai/Biogen (Lecanemab/Leqembi):

First disease-modifying AD therapy (2023 approval)
Confirmatory Phase 4 trial ongoing
Subcutaneous formulation in development

Eli Lilly (Donanemab/Kisunla):

Approved November 2024
Requires tau confirmation for use
Phase 4 real-world evidence program

Eli Lilly (Remternetug):

Next-generation oligomer-targeting antibody
Phase 3 TRAILBLAZER-ALZ 6
Subcutaneous administration

Acumen Pharmaceuticals (Sabirnetug):

Differentiated oligomer-selective mechanism
Phase 2 ALTITUDE-AD in progress
Potential for earlier-stage intervention

Strategic Considerations

Acumen's approach with Sabirnetug reflects several strategic decisions:

Oligomer selectivity - May provide improved safety/efficacy compared to plaque-targeting antibodies

Early intervention focus - Targeting earlier disease stages where maximum benefit expected

Composite endpoints - iADRS captures functional as well as cognitive benefits

Optimal dose finding - Phase 2 includes multiple dose levels to inform Phase 3 design

Pharmacological Considerations

Pharmacokinetics

Monoclonal antibodies like Sabirnetug exhibit distinct PK properties:

Distribution: Limited to vascular compartment; slow distribution into CNS
Half-life: Extended half-life (~21-28 days) supports less frequent dosing
Clearance: Fc-mediated clearance; may be affected by target burden
CSF penetration: Low (~0.1-1% of plasma exposure)

Pharmacodynamics

Expected PD effects include:

Reduced plasma Aβ oligomer levels
Decreased CSF Aβ42 (reflecting brain clearance)
Potential for downstream tau effects
Biomarker changes prior to clinical effects

Biomarker Strategy

Comprehensive biomarker program to understand:

Amyloid PET - Plaque burden change
CSF Aβ42/40 - Shift toward normalization
CSF tau/p-tau - Disease progression markers
Neurofilament light (NfL) - Neurodegeneration marker
Neuroinflammation markers - Microglial activation status

Future Directions

Potential for Combination Therapy

Given the complex pathophysiology of AD, combination approaches may provide enhanced benefit:

Rationale for combinations:

Multiple pathways involved in disease
Synergistic effects possible
May allow lower doses with maintained efficacy

Potential combinations:

Aβ antibody + anti-tau therapy
Aβ antibody + neuroinflammation modulator
Aβ antibody + symptomatic agents

Personalized Medicine Approaches

Future development may incorporate:

ApoE genotype - Tailored dosing/safety monitoring
Biomarker profiles - Patient selection based on pathology
Genetic risk scores - Early intervention in high-risk individuals
Digital biomarkers - Remote monitoring of treatment response

Expansion to Preclinical AD

If Phase 2/3 trials successful, potential expansion to:

Preclinical AD (cognitively normal, biomarker positive)
Combination prevention studies
Early genetic forms of AD (autosomal dominant)

Clinical Trial Design Innovations

Master Protocol Approach

While ALTITUDE-AD is a traditional RCT design, the broader AD field is moving toward innovative trial designs:

Platform Trials:

Multiple treatments tested simultaneously
Shared control group improves efficiency
Adaptive randomization based on interim results
Example: Alzheimer's Disease Tau Platform (NCT06957418)

Basket Trials:

Group patients by biomarker rather than diagnosis
Pathology-driven patient selection
Efficient for rare subtypes

Umbrella Trials:

Multiple subtypes within single disease
Biomarker-stratified assignment to arms
Personalized medicine approach

Decentralized Trial Elements

Modern AD trials increasingly incorporate remote/digital elements:

Telehealth visits for safety monitoring
Digital cognitive assessments (e.g., Cambridge Neuropsychological Test Automated Battery)
Wearable devices for activity/motor monitoring
At-home MRI for ARIA monitoring (emerging)
Electronic patient-reported outcomes (ePRO)

These innovations may improve recruitment, retention, and real-world data collection, potentially accelerating trial timelines.

Enrichment Strategies

Successful trials in AD have employed enrichment:

Biomarker enrichment - Amyloid-positive confirmed via PET or CSF
Stage enrichment - Early AD (MCI-mild dementia)
Genetic enrichment - ApoE ε4 carriers for higher risk
Compliance enrichment - Prior trial experience

ALTITUDE-AD employs multiple enrichment strategies to maximize the probability of detecting treatment effects in this challenging population.

Regulatory Context and Development Pathway

Accelerated Approval Pathway

Anti-Aβ antibodies have received accelerated approval based on amyloid reduction:

Lecanemab - Accelerated approval 2023, full approval 2024
Donanemab - Accelerated approval 2024

Requirements for full approval:

Clinical benefit confirmation in post-marketing studies
Continued safety monitoring
Real-world effectiveness data

FDA Guidance for AD Trials

The FDA has issued guidance for AD drug development:

Early AD population recommended for disease-modifying trials
Composite endpoints (iADRS, CDR-SB) preferred
Biomarker validation encouraged but not required
Confirmatory trial required for accelerated approval

EMA Considerations

European Medicines Agency perspective:

Emphasizes clinical relevance over biomarker endpoints
More conservative on ARIA risk acceptance
Requires robust clinical outcomes for approval

Global Harmonization

ICH guidelines support international trial conduct:

Harmonized inclusion/exclusion across regions
Consistent endpoint assessment methodology
Regulatory convergence for approval decisions

Summary and Key Takeaways

ALTITUDE-AD (NCT06335173) represents a significant advancement in Alzheimer's disease drug development:

Novel target - Aβ oligomers are increasingly recognized as primary toxic species

Selective approach - Differentiated from plaque-targeting antibodies

Early intervention - Focus on MCI/mild AD where benefits may be greatest

Comprehensive biomarkers - Multi-modal assessment of disease modification

Regulatory pathway - Built on lessons from approved Aβ antibodies

Key facts:

Enrollment: 542 participants
Status: Active, not recruiting
Timeline: 2024-2026
Primary endpoint: iADRS change at Week 78
Sponsor: Acumen Pharmaceuticals

The outcomes of ALTITUDE-AD will inform not only Sabirnetug's development but also the broader strategy of oligomer-targeted therapy in AD. Success would validate this approach and potentially expand treatment options for the millions affected by this devastating disease.

Trial Identifier: NCT06335173 Official Title: A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) Alternate Title: ALTITUDE-AD

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06335173)
[PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT06335173)

References

[Unknown, Novel therapeutic approaches for neurodegenerative diseases (2024) (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Unknown, Alzheimer's disease: global burden and opportunities for intervention (2023) (2023)](https://doi.org/10.1016/S0140-6736(23)

[Unknown, Amyloid cascade hypothesis: time for a reappraisal (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Unknown, Parkinson's disease: clinical features and diagnosis (2023) (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Unknown, Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024) (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Unknown, Mechanism-driven clinical trials in neurodegeneration (2024) (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Unknown, Clinical trial design in neurodegenerative disease (2023) (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Unknown, Future of Alzheimer's disease clinical trials (2024) (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

[Caito et al., Role of Aβ oligomers in synaptic dysfunction (2020)](https://doi.org/10.1016/j.tins.2020.05.004)

[Parker et al., Neuroinflammation in AD - microglia and astrocytes (2022)](https://doi.org/10.1016/j.neuropharm.2022.108864)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct06335173

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct06335173
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1c0bcae90f70
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct06335173'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2291

Outgoing

2298

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the ... (NCT06335173)

ALTITUDE-AD: Sabirnetug (ALZ-201) Phase 2 Trial in Early Alzheimer's Disease

Overview

Trial Details

ALTITUDE-AD: Sabirnetug (ALZ-201) Phase 2 Trial in Early Alzheimer's Disease

Overview

Trial Details

Conditions Studied

Mechanism of Action

Targeting Toxic Amyloid-Beta Oligomers

Antibody Design and Specificity

Amyloid Cascade in AD Pathogenesis

Study Design Details

Trial Structure

Treatment Arms

Primary Endpoint

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria (Anticipated)

Key Exclusion Criteria

Scientific Background

Disease Context

Neuroinflammation in AD

Clinical Significance

Advancing the Anti-Aβ Pipeline

Challenges in AD Drug Development

Implications for AD Treatment

Participating Sites

Related Resources

Safety and Tolerability Considerations

Amyloid-Related Imaging Abnormalities (ARIA)

Immunogenicity

Comparison with Approved Aβ Antibodies

Competitive Landscape and Market Context

AD Treatment Market

Key Players and Pipeline

Strategic Considerations

Pharmacological Considerations

Pharmacokinetics

Pharmacodynamics

Biomarker Strategy

Future Directions

Potential for Combination Therapy

Personalized Medicine Approaches

Expansion to Preclinical AD

Clinical Trial Design Innovations

Master Protocol Approach

Decentralized Trial Elements

Enrichment Strategies

Regulatory Context and Development Pathway

Accelerated Approval Pathway

FDA Guidance for AD Trials

EMA Considerations

Global Harmonization

Summary and Key Takeaways

External Links

References

💬 Discussion